GNF-6231

GNF-6231 is a porcupine (IC50= 0.8 nM), Pron, and endoplasmic reticulum protein inhibitor with oral activity. GNF-6231 has anticancer activity. GNF-6231 can prevent the activation of the Wnt pathway by blocking the secretion of all Wnt ligands. GNF-6231 can be used in the study of myocardial infarction[1][2][3][4].

[1]Bastakoty, Dikshya et al. Temporary, Systemic Inhibition of the WNT/β-Catenin Pathway promotes Regenerative Cardiac Repair following Myocardial Infarct. Cell, stem cells and regenerative medicine vol. 2,2 (2016): 10.16966/2472-6990.111. |[2]Kang, Sheng. Low-density lipoprotein receptor-related protein 6-mediated signaling pathways and associated cardiovascular diseases: diagnostic and therapeutic opportunities. Human genetics vol. 139,4 (2020): 447-459. |[3]Raeisi, Mortaza et al. Porcn as a novel therapeutic target in cancer therapy:  A review. Cell biology international vol. 46,12 (2022): 1979-1991.|[4]Cheng, Dai et al. Discovery of Pyridinyl Acetamide Derivatives as Potent, Selective, and Orally Bioavailable Porcupine Inhibitors. ACS medicinal chemistry letters vol. 7,7 676-80. 10 May. 2016, |[5]Bastakoty, Dikshya et al. Temporary, Systemic Inhibition of the WNT/β-Catenin Pathway promotes Regenerative Cardiac Repair following Myocardial Infarct. Cell, stem cells and regenerative medicine vol. 2,2 (2016): 10.16966/2472-6990.111.